Literature DB >> 22488449

Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica.

Bhupendra O Khatri1, John Kramer, Mary Dukic, Mauricio Palencia, William Verre.   

Abstract

Neuromyelitis optica (NMO) is a severe inflammatory demyelinating disease of the central nervous system with exacerbations involving the optic nerves, spinal cord, or both. This study explores the utility of maintenance plasma exchange (mTPE) as a therapy in patients with relapsing, corticosteroid-refractory, NMO. This retrospective case series presents data on patients who were diagnosed with NMO using currently accepted criteria. These patients were refractory to high-dose corticosteroids and received mTPE. Seven patients met the criteria for NMO diagnosis and all were positive for antibodies against aquaporin-4. Over a mean of 7.1 years (range, 2-16), these patients received between 21 and 154 TPE treatments (mean, 76). Although treated with mTPE, five out of the seven patients improved by more than one point on the Expanded Disability Status Scale. Interruption in mTPE in five patients resulted in clinical worsening. When mTPE was restarted in three out of the five patients who experienced a cessation of mTPE, these patients either stabilized or improved. The two patients who did not restart the mTPE protocol died. Patients treated with mTPE also experienced a reduction in the number of NMO exacerbations. Finally, stabilization of the retinal nerve fiber layer thickness was observed while on mTPE. In this preliminary study, mTPE appeared safe and may bring about improvement in disability and sustained stabilization of the clinical course in patients with steroid-refractory relapsing forms of NMO.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488449     DOI: 10.1002/jca.21215

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  15 in total

1.  [Therapeutic options for autoimmune encephalomyelitis].

Authors:  N Borisow; H Prüss; F Paul
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

2.  Optic neuritis in neuromyelitis optica.

Authors:  Marc H Levin; Jeffrey L Bennett; A S Verkman
Journal:  Prog Retin Eye Res       Date:  2013-03-30       Impact factor: 21.198

3.  Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.

Authors:  Kristin M Ikeda; Donald H Lee; J Alexander Fraser; Seyed Mirsattari; Sarah A Morrow
Journal:  Int J MS Care       Date:  2015 Sep-Oct

Review 4.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

5.  Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.

Authors:  Ilya Ayzenberg; Joanna Schöllhammer; Robert Hoepner; Kerstin Hellwig; Marius Ringelstein; Orhan Aktas; Tania Kümpfel; Markus Krumbholz; Corinna Trebst; Friedemann Paul; Florence Pache; Mark Obermann; Lena Zeltner; Matthias Schwab; Achim Berthele; Sven Jarius; Ingo Kleiter
Journal:  J Neurol       Date:  2016-01-25       Impact factor: 4.849

Review 6.  [Neuromyelitis optica].

Authors:  B Wildemann; S Jarius; F Paul
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

Review 7.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 8.  [Treatment of antibody-mediated encephalomyelitis : Strategies for the treatment of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease].

Authors:  Ilya Ayzenberg; Ingo Kleiter
Journal:  Nervenarzt       Date:  2021-03-30       Impact factor: 1.214

Review 9.  Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.

Authors:  J L Bennett; J de Seze; M Lana-Peixoto; J Palace; A Waldman; S Schippling; S Tenembaum; B Banwell; B Greenberg; M Levy; K Fujihara; K H Chan; H J Kim; N Asgari; D K Sato; A Saiz; J Wuerfel; H Zimmermann; A Green; P Villoslada; F Paul
Journal:  Mult Scler       Date:  2015-02-06       Impact factor: 6.312

Review 10.  Immunotherapy of neuromyelitis optica.

Authors:  Benjamin Bienia; Roumen Balabanov
Journal:  Autoimmune Dis       Date:  2013-12-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.